An initial safety study of Gedatolisib plus PTK7-ADC for metastatic triple-negative breast cancer

K
Kathy Miller, MD

Primary Investigator

Overview

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer.

Description

The purpose of this study is to evaluate the safety of Gedatolisib plus PTK7-ADC in patients with metastatic triple-negative or estrogen poor breast cancer as assessed by NCI CTC v4.0 criteria.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    breast cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Metastatic Triple-negative Breast Cancer
Willingness to undergo tumor biopsy
Patients must have received at least 1 prior chemotherapy regimen for metastatic disease
Exclusion Criteria
Previous treatment with mTOR inhibitor
Untreated brain metastases


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1704239900 (IUSCC-0613)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center